• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconGLP-1s

GLP-1s

gila
Commentary
What a desert lizard teaches us about patents and the GLP-1 revolution
By Dr. Bowman HeidenOctober 10, 2026
Ro GLP-1 Review (2026): Everything You Need to Know
Health
Ro GLP-1 Review (2026): Everything You Need to Know
By Christina SnyderOctober 9, 2026
The 7 Best Online GLP-1 Programs of 2026: Reviewed by Experts
Health
The 7 Best Online GLP-1 Programs of 2026: Reviewed by Experts
By Emily PharesOctober 7, 2026
I’m an obesity expert and can’t wait for the compounding craze to stop
Commentary
I’m an obesity expert and can’t wait for the compounding craze to stop
By Adonis SaremiOctober 3, 2026
Logo for the 24 hour McDonalds fast food restaurant on 11th July 2026 in London, United Kingdom.
Health
Forget supersized: McDonald’s is exploring an $8.5 billion bet on an American fast food wave led by proteinmaxxing, portion control, and GLP-1s
By Joshua HongOctober 1, 2026
Noom GLP-1 Review (2026): Everything You Need to Know About Noom Med
Health
Noom GLP-1 Review (2026): Everything You Need to Know About Noom Med
By Christina SnyderSeptember 23, 2026
Miami Beach Florida, CVS Pharmacy, pharmacist talking to customer, technician organizing medicine shelves.
Economy
U.S. demand for Novo Nordisk’s weight loss drugs is so huge that the Danish central bank just doubled the nation’s entire growth forecast
By Eleanor PringleSeptember 23, 2026
The Best Online Semaglutide Programs (2026): MD Approved
Health
The Best Online Semaglutide Programs (2026): MD Approved
By Christina SnyderSeptember 22, 2026
Jeff La Marca
Health
The Medicare GLP-1 discount is here, so why are some sick people excluded?
By Jackie Fortiér and KFF Health NewsAugust 25, 2026
t
Health
‘Game-changer’ GLP-1s could fix America’s obesity crisis—but 2 inequalities stand in the way
By Nick LichtenbergAugust 20, 2026
glp
Commentary
The hidden risk of GLP-1 drugs
By Jessica Starr and Emily SteinAugust 14, 2026
Brian Moynihan, chief executive officer of Bank of America
Success
Bank of America is splashing out $250 million a year on weight loss drugs for its staff: ‘We see a great impact on employees,’ CEO says
By Emma BurleighAugust 7, 2026
glp
Commentary
The GLP-1 paradox: too expensive to cover, too effective to cut
By Bryan Sivak and Elina OnitskanskyJuly 23, 2026
Sean McClain wears a lab coat
Startups & Venture
Eli Lilly just placed a $40 million bet on the next injectable boom
By Lily Mae LazarusJuly 1, 2026
A pedestrian walks past a Gucci luxury fashion store at a shopping district on June 24, 2026, in Shenzhen, Guangdong Province, China.
Retail
Rich consumers taking GLP-1s are rebuying their wardrobes and eating smaller, fancier dishes—it’s a factor saving the luxury sector right now
By Eleanor PringleJune 25, 2026
1
  • 1
  • 2
  • 3
  • 4
4
Most Popular
Success
MacKenzie Scott alone accounted for one-third of America's $19.2 billion in megagifts last yearplaceholder alt text
By Sydney LakeOctober 11, 2026
Big Tech
Nvidia built a $5 trillion company while making employees pay for their own lunch—but they get far more lucrative perks like stock discountsplaceholder alt text
By Marco Quiroz-GutierrezOctober 10, 2026
Success
Palantir’s billionaire CEO says only two kinds of people will succeed in the AI era: trade workers—‘or you’re neurodivergent’placeholder alt text
By Preston ForeOctober 10, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.